Cargando…

The Effectiveness of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis, Familial Pulmonary Fibrosis and Progressive Fibrosing Interstitial Lung Diseases: A Real-World Study

Background: Nintedanib is an oral multitarget tyrosine kinase inhibitor approved for the treatment of patients with idiopathic pulmonary fibrosis (IPF). Recent evidence demonstrated that nintedanib reduced functional disease progression also in subjects with non-IPF progressive fibrosing interstitia...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cameli, Paolo, Alonzi, Valerio, d’Alessandro, Miriana, Bergantini, Laura, Pordon, Elena, Guerrieri, Marco, Refini, Rosa Metella, Sestini, Piersante, Bargagli, Elena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9405731/ https://www.ncbi.nlm.nih.gov/pubmed/36009520 http://dx.doi.org/10.3390/biomedicines10081973

Ejemplares similares

Long-Term Follow-Up of Patients With Idiopathic Pulmonary Fibrosis Treated With Pirfenidone or Nintedanib: A Real-Life Comparison Study
por: Cameli, Paolo, et al.
Publicado: (2020)

Metabolic Dysregulation in Idiopathic Pulmonary Fibrosis
por: Bargagli, Elena, et al.
Publicado: (2020)

The role of the combination of echo-HRCT score as a tool to evaluate the presence of pulmonary hypertension in idiopathic pulmonary fibrosis
por: Refini, Rosa Metella, et al.
Publicado: (2020)

Adaptive immune system in pulmonary sarcoidosis—Comparison of peripheral and alveolar biomarkers
por: d’Alessandro, Miriana, et al.
Publicado: (2021)

Extended Exhaled Nitric Oxide Analysis in Interstitial Lung Diseases: A Systematic Review
por: Cameli, Paolo, et al.
Publicado: (2020)

Pirfenidone in idiopathic pulmonary fibrosis: real-life experience in the referral centre of Siena
por: Vietri, Lucia, et al.
Publicado: (2020)

Serum Concentrations of KL-6 in Patients with IPF and Lung Cancer and Serial Measurements of KL-6 in IPF Patients Treated with Antifibrotic Therapy
por: d’Alessandro, Miriana, et al.
Publicado: (2021)

Idiopathic Pulmonary Fibrosis Serum proteomic analysis before and after nintedanib therapy
por: Landi, Claudia, et al.
Publicado: (2020)

Systematic Review and Metanalysis of Oncomarkers in IPF Patients and Serial Changes of Oncomarkers in a Prospective Italian Real-Life Case Series
por: d’Alessandro, Miriana, et al.
Publicado: (2021)

Common Molecular Pathways Between Post-COVID19 Syndrome and Lung Fibrosis: A Scoping Review
por: Bergantini, Laura, et al.
Publicado: (2022)

Hypercalciuria in Sarcoidosis: A Specific Biomarker With Clinical Utility
por: Cameli, Paolo, et al.
Publicado: (2020)

Extracellular Vesicles in Pulmonary Fibrosis Models and Biological Fluids of Interstitial Lung Disease Patients: A Scoping Review
por: d’Alessandro, Miriana, et al.
Publicado: (2021)

Utility of serological biomarker’ panels for diagnostic accuracy of interstitial lung diseases
por: Bergantini, Laura, et al.
Publicado: (2020)

Oxygen Therapy during Exercise in Patients with Interstitial Lung Diseases
por: Viani, Magda, et al.
Publicado: (2022)

Prognostic Significance of Obstructive Sleep Apnea in a Population of Subjects with Interstitial Lung Diseases
por: Valecchi, Debora, et al.
Publicado: (2023)

Follicular T Helper and Breg Cell Balance in Severe Allergic Asthma Before and After Omalizumab Therapy
por: Bergantini, Laura, et al.
Publicado: (2021)

Alveolar Nitric Oxide as a Biomarker of COVID-19 Lung Sequelae: A Pivotal Study
por: Cameli, Paolo, et al.
Publicado: (2021)

Correction to: Chitotriosidase: a biomarker of activity and severity in patients with sarcoidosis
por: Bennett, David, et al.
Publicado: (2020)

Combined Sarcoidosis and Idiopathic Pulmonary Fibrosis (CSIPF): A New Phenotype or a Fortuitous Overlap? Scoping Review and Case Series
por: Bergantini, Laura, et al.
Publicado: (2022)

Bronchoalveolar-Lavage-Derived Fibroblast Cell Line (B-LSDM7) as a New Protocol for Investigating the Mechanisms of Idiopathic Pulmonary Fibrosis
por: Bergantini, Laura, et al.
Publicado: (2022)

NK and T Cell Immunological Signatures in Hospitalized Patients with COVID-19
por: Bergantini, Laura, et al.
Publicado: (2021)

Chitotriosidase: a biomarker of activity and severity in patients with sarcoidosis
por: Bennett, David, et al.
Publicado: (2020)

Exploring the Interaction between Fractional Exhaled Nitric Oxide and Biologic Treatment in Severe Asthma: A Systematic Review
por: Pianigiani, Tommaso, et al.
Publicado: (2023)

Prevalence of myositis specific and associated antibodies in a cohort of patients affected by idiopathic NSIP and no hint of inflammatory myopathies
por: Conticini, Edoardo, et al.
Publicado: (2023)

Clinical phenotyping in sarcoidosis management
por: Rana, Giuseppe Domenico, et al.
Publicado: (2021)

Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis who are elderly or have comorbidities
por: Glaspole, Ian, et al.
Publicado: (2021)

Effect of Ambulatory Oxygen on the Respiratory Pattern during the 6 Min Walking Test in Patients with Interstitial Lung Diseases
por: Ventura, Vittoria, et al.
Publicado: (2023)

Neutrophil Extracellular Traps in ANCA-Associated Vasculitis and Interstitial Lung Disease: A Scoping Review
por: d’Alessandro, Miriana, et al.
Publicado: (2022)

Beyond idiopathic pulmonary fibrosis: the world of progressive-fibrosing interstitial lung disease
por: Harari, Sergio
Publicado: (2018)

Pathogenesis of idiopathic pulmonary fibrosis: review of recent findings
por: Renzoni, Elisabetta, et al.
Publicado: (2014)

High-dose steroids for the treatment of severe COVID-19: a new therapeutic tool?
por: Cameli, Paolo, et al.
Publicado: (2021)

MR-proADM as Prognostic Factor of Outcome in COVID-19 Patients
por: Cameli, Paolo, et al.
Publicado: (2023)

Cytomegalovirus Infection Is Associated with Development of Chronic Lung Allograft Dysfunction
por: Bennett, David, et al.
Publicado: (2022)

Pulmonary Hypertension Exacerbated by Nintedanib Administration for Idiopathic Pulmonary Fibrosis
por: Shimomura, Iwao, et al.
Publicado: (2018)

Nintedanib in children and adolescents with fibrosing interstitial lung diseases
por: Deterding, Robin, et al.
Publicado: (2023)

Effects of Nintedanib on Quantitative Lung Fibrosis Score in Idiopathic Pulmonary Fibrosis
por: Lancaster, Lisa, et al.
Publicado: (2020)

Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis
por: Wollin, Lutz, et al.
Publicado: (2015)

Treatment with nintedanib for acute exacerbation of idiopathic pulmonary fibrosis
por: Tomioka, Hiromi, et al.
Publicado: (2017)

Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis
por: Yoon, Hee-Young, et al.
Publicado: (2018)

Clinical use of nintedanib in patients with idiopathic pulmonary fibrosis
por: Hajari Case, Amy, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_u3g9346asa4195o6pg3j71bm97